VYOME HOLDINGS INC (HIND) Fundamental Analysis & Valuation

NASDAQ:HIND • US92943X1046

2.25 USD
-0.12 (-5.06%)
At close: Mar 13, 2026
2.2584 USD
+0.01 (+0.37%)
After Hours: 3/13/2026, 6:35:55 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This HIND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, HIND scores 2 out of 10 in our fundamental rating. HIND was compared to 193 industry peers in the Pharmaceuticals industry. While HIND seems to be doing ok healthwise, there are quite some concerns on its profitability. HIND is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. HIND Profitability Analysis

1.1 Basic Checks

  • HIND had negative earnings in the past year.
  • In the past year HIND has reported a negative cash flow from operations.
  • HIND had negative earnings in each of the past 5 years.
  • In the past 5 years HIND always reported negative operating cash flow.
HIND Yearly Net Income VS EBIT VS OCF VS FCFHIND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • HIND's Return On Assets of -161.11% is on the low side compared to the rest of the industry. HIND is outperformed by 85.49% of its industry peers.
  • HIND has a worse Return On Equity (-448.70%) than 78.76% of its industry peers.
Industry RankSector Rank
ROA -161.11%
ROE -448.7%
ROIC N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HIND Yearly ROA, ROE, ROICHIND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

  • HIND's Gross Margin of 62.39% is fine compared to the rest of the industry. HIND outperforms 71.50% of its industry peers.
  • In the last couple of years the Gross Margin of HIND has grown nicely.
  • HIND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
HIND Yearly Profit, Operating, Gross MarginsHIND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. HIND Health Analysis

2.1 Basic Checks

  • HIND does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HIND has been increased compared to 1 year ago.
  • Compared to 5 years ago, HIND has more shares outstanding
  • Compared to 1 year ago, HIND has a worse debt to assets ratio.
HIND Yearly Shares OutstandingHIND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5K 10K 15K
HIND Yearly Total Debt VS Total AssetsHIND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • HIND has an Altman-Z score of -16.82. This is a bad value and indicates that HIND is not financially healthy and even has some risk of bankruptcy.
  • HIND's Altman-Z score of -16.82 is on the low side compared to the rest of the industry. HIND is outperformed by 80.31% of its industry peers.
  • There is no outstanding debt for HIND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.82
ROIC/WACCN/A
WACC9.45%
HIND Yearly LT Debt VS Equity VS FCFHIND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.94 indicates that HIND should not have too much problems paying its short term obligations.
  • HIND's Current ratio of 1.94 is on the low side compared to the rest of the industry. HIND is outperformed by 61.66% of its industry peers.
  • A Quick Ratio of 1.94 indicates that HIND should not have too much problems paying its short term obligations.
  • HIND has a Quick ratio of 1.94. This is comparable to the rest of the industry: HIND outperforms 46.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.94
HIND Yearly Current Assets VS Current LiabilitesHIND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. HIND Growth Analysis

3.1 Past

  • HIND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.16%, which is quite impressive.
  • Looking at the last year, HIND shows a very negative growth in Revenue. The Revenue has decreased by -48.74% in the last year.
  • The Revenue has been growing by 19.54% on average over the past years. This is quite good.
EPS 1Y (TTM)90.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.02%
Revenue 1Y (TTM)-48.74%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-98.49%

3.2 Future

  • Based on estimates for the next years, HIND will show a very negative growth in Earnings Per Share. The EPS will decrease by -45.64% on average per year.
  • Based on estimates for the next years, HIND will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-604.44%
EPS Next 2Y-34.99%
EPS Next 3Y-45.64%
EPS Next 5YN/A
Revenue Next Year-97.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HIND Yearly Revenue VS EstimatesHIND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
HIND Yearly EPS VS EstimatesHIND Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5M -10M -15M -20M

More info and screens

Find the best growth stocksShow best growing peers

0

4. HIND Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HIND. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HIND. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HIND Price Earnings VS Forward Price EarningsHIND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HIND Per share dataHIND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

  • HIND's earnings are expected to decrease with -45.64% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.99%
EPS Next 3Y-45.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HIND Dividend Analysis

5.1 Amount

  • No dividends for HIND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HIND Fundamentals: All Metrics, Ratios and Statistics

VYOME HOLDINGS INC

NASDAQ:HIND (3/13/2026, 6:35:55 PM)

After market: 2.2584 +0.01 (+0.37%)

2.25

-0.12 (-5.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)04-02
Inst Owners2.96%
Inst Owner Change286.19%
Ins Owners26.79%
Ins Owner Change0%
Market Cap12.69M
Revenue(TTM)4.19M
Net Income(TTM)-11.35M
Analysts82.86
Price Target15.3 (580%)
Short Float %5.8%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.03
P/FCF N/A
P/OCF N/A
P/B 5.02
P/tB 5.73
EV/EBITDA N/A
EPS(TTM)-183.13
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.74
BVpS0.45
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -161.11%
ROE -448.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.39%
FCFM N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.94
Altman-Z -16.82
F-Score3
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.02%
EPS Next Y-604.44%
EPS Next 2Y-34.99%
EPS Next 3Y-45.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-48.74%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-98.49%
Revenue Next Year-97.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y31.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y83.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.93%
OCF growth 3YN/A
OCF growth 5YN/A

VYOME HOLDINGS INC / HIND FAQ

Can you provide the ChartMill fundamental rating for VYOME HOLDINGS INC?

ChartMill assigns a fundamental rating of 2 / 10 to HIND.


Can you provide the valuation status for VYOME HOLDINGS INC?

ChartMill assigns a valuation rating of 0 / 10 to VYOME HOLDINGS INC (HIND). This can be considered as Overvalued.


What is the profitability of HIND stock?

VYOME HOLDINGS INC (HIND) has a profitability rating of 1 / 10.


What is the financial health of VYOME HOLDINGS INC (HIND) stock?

The financial health rating of VYOME HOLDINGS INC (HIND) is 4 / 10.